Literature DB >> 2863104

Biochemical properties of blood esmolol esterase.

C Y Quon, H F Stampfli.   

Abstract

The blood esterase mediating the hydrolysis of esmolol was characterized in several different species including man. In contrast to most ester-containing drugs, hydrolysis of esmolol was mediated by an esterase in the cytosol of red blood cells (RBC) in man and dogs and not in plasma or RBC membrane. Species differences in the esterase activity existed. Guinea pig and rat blood esterase activities were much greater than those in the dog followed by those in man. In addition, the esterase activity in rat and guinea pig blood was localized in plasma and not in RBC. Purified human serum cholinesterase, human RBC membrane acetylcholinesterase, human hemoglobin, human carbonic anhydrases A and B, and human and dog serum albumin were all inactive against esmolol. Esmolol esterase activity in human and dog blood was inhibited by sodium fluoride, EDTA, and p-hydroxymercuribenzoate, but not by echothiophate, eserine, and acetazolamide. In contrast, echothiophate and sodium fluoride, but not eserine, inhibited the esterase activity in rat and guinea pig plasma. Metabolic interaction studies indicated that acetylcholine, succinylcholine, procaine, and chloroprocaine did not interfere with the metabolism of esmolol by human and dog blood. Based on the results, it appeared that an arylesterase in human and dog RBC cytosol mediated the hydrolysis of esmolol while an aliphatic esterase mediated the hydrolysis of esmolol in guinea pig and rat plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863104

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Esmolol--just another beta blocker?

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

2.  Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.

Authors:  Niklas Lindegardh; Geraint R Davies; Tinh Hien Tran; Jeremy Farrar; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function.

Authors:  Joseph F Cotten; Ri Le Ge; Natalie Banacos; Ervin Pejo; S Shaukat Husain; James H Williams; Douglas E Raines
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

4.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

5.  In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate.

Authors:  Ervin Pejo; Joseph F Cotten; Elizabeth W Kelly; Ri Le Ge; Gregory D Cuny; Joydev K Laha; Jifeng Liu; Xiang Jie Lin; Douglas E Raines
Journal:  Anesth Analg       Date:  2011-09-29       Impact factor: 5.108

6.  The pharmacokinetics and electroencephalogram response of remifentanil alone and in combination with esmolol in the rat.

Authors:  S H Haidar; J E Moreton; Z Liang; J F Hoke; K T Muir; N D Eddington
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

Review 7.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.

Authors:  D Wiest
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

8.  Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.

Authors:  H S Yang; W M Wu; N Bodor
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

9.  Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species.

Authors:  L Qi-Gui; Z Ming-Da; M Hümpel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

Review 10.  Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P Benfield; E M Sorkin
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.